Cargando…
CD22: A Regulator of Innate and Adaptive B Cell Responses and Autoimmunity
CD22 (Siglec 2) is a receptor predominantly restricted to B cells. It was initially characterized over 30 years ago and named “CD22” in 1984 at the 2nd International workshop in Boston (1). Several excellent reviews have detailed CD22 functions, CD22-regulated signaling pathways and B cell subsets r...
Autores principales: | Clark, Edward A., Giltiay, Natalia V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6173129/ https://www.ncbi.nlm.nih.gov/pubmed/30323814 http://dx.doi.org/10.3389/fimmu.2018.02235 |
Ejemplares similares
-
B cell-activating factor (BAFF) from dendritic cells, monocytes and neutrophils is required for B cell maturation and autoantibody production in SLE-like autoimmune disease
por: Giordano, Daniela, et al.
Publicado: (2023) -
Targeting CD22 with the monoclonal antibody epratuzumab modulates human B-cell maturation and cytokine production in response to Toll-like receptor 7 (TLR7) and B-cell receptor (BCR) signaling
por: Giltiay, Natalia V., et al.
Publicado: (2017) -
Anti-CD40 antibody KPL-404 inhibits T cell-mediated activation of B cells from healthy donors and autoimmune patients
por: Marken, John, et al.
Publicado: (2021) -
Correction to: Anti-CD40 antibody KPL-404 inhibits T cell-mediated activation of B cells from healthy donors and autoimmune patients
por: Marken, John, et al.
Publicado: (2021) -
Targeting CD22 Reprograms B-Cells and Reverses Autoimmune Diabetes
por: Fiorina, Paolo, et al.
Publicado: (2008)